VKTX AASLD data: https://www.prnewswire.com/news-releases/viking-therapeutics-presents-results-from-phase-2-study-of-vk2809-in-patients-with-non-alcoholic-fatty-liver-disease-nafld-and-elevated-ldl-cholesterol-in-oral-late-breaker-presentation-at-the-liver-meeting-2018-300748744.html Comments: https://twitter.com/gcbioinv/status/1062135499232632834 This looks like best-in-class by a long shot from an initial read of the data. So again why is VKTX worth one-third of Madrigal?